Suppr超能文献

即时 C 反应蛋白检测在改善阿富汗疟疾阴性患者抗生素处方方面的成本效益,与当前临床实践相比。

Cost-effectiveness of point-of-care C-Reactive Protein test compared to current clinical practice as an intervention to improve antibiotic prescription in malaria-negative patients in Afghanistan.

机构信息

Mott MacDonald Ltd, London, United Kingdom.

Health Economics Research Unit, University of Aberdeen, Aberdeen, United Kingdom.

出版信息

PLoS One. 2021 Nov 8;16(11):e0258299. doi: 10.1371/journal.pone.0258299. eCollection 2021.

Abstract

BACKGROUND

Antimicrobial resistance (AMR) is a global health problem requiring a reduction in inappropriate antibiotic prescribing. Point-of-Care C-Reactive Protein (POCCRP) tests could distinguish between bacterial and non-bacterial causes of fever in malaria-negative patients and thus reduce inappropriate antibiotic prescribing. However, the cost-effectiveness of POCCRP testing is unclear in low-income settings.

METHODS

A decision tree model was used to estimate cost-effectiveness of POCCRP versus current clinical practice at primary healthcare facilities in Afghanistan. Data were analysed from healthcare delivery and societal perspectives. Costs were reported in 2019 USD. Effectiveness was measured as correctly treated febrile malaria-negative patient. Cost, effectiveness and diagnostic accuracy parameters were obtained from primary data from a cost-effectiveness study on malaria rapid diagnostic tests in Afghanistan and supplemented with POCCRP-specific data sourced from the literature. Incremental cost-effectiveness ratios (ICERs) reported the additional cost per additional correctly treated febrile malaria-negative patient over a 28-day time horizon. Univariate and probabilistic sensitivity analyses examined the impact of uncertainty of parameter inputs. Scenario analysis included economic cost of AMR per antibiotic prescription.

RESULTS

The model predicts that POCCRP intervention would result in 137 fewer antibiotic prescriptions (6%) with a 12% reduction (279 prescriptions) in inappropriate prescriptions compared to current clinical practice. ICERs were $14.33 (healthcare delivery), $11.40 (societal), and $9.78 (scenario analysis) per additional correctly treated case.

CONCLUSIONS

POCCRP tests could improve antibiotic prescribing among malaria-negative patients in Afghanistan. Cost-effectiveness depends in part on willingness to pay for reductions in inappropriate antibiotic prescribing that will only have modest impact on immediate clinical outcomes but may have long-term benefits in reducing overuse of antibiotics. A reduction in the overuse of antibiotics is needed and POCCRP tests may add to other interventions in achieving this aim. Assessment of willingness to pay among policy makers and donors and undertaking operational trials will help determine cost-effectiveness and assist decision making.

摘要

背景

抗菌药物耐药性(AMR)是一个全球性的健康问题,需要减少不合理的抗生素处方。即时检测 C 反应蛋白(POCCRP)测试可以区分疟疾阴性患者发热的细菌和非细菌原因,从而减少不合理的抗生素处方。然而,POCCRP 检测在低收入环境中的成本效益尚不清楚。

方法

使用决策树模型来评估 POCCRP 与阿富汗初级保健机构当前临床实践相比的成本效益。数据从医疗服务提供和社会两个角度进行分析。成本以 2019 年美元表示。有效性以正确治疗发热性疟疾阴性患者来衡量。成本、效果和诊断准确性参数是从阿富汗疟疾快速诊断检测的成本效益研究中获得的原始数据得出的,并辅以从文献中获得的 POCCRP 特定数据进行补充。增量成本效益比(ICER)报告了在 28 天时间内,每增加一名正确治疗发热性疟疾阴性患者的额外成本。单变量和概率敏感性分析检查了参数输入不确定性的影响。情景分析包括每处方抗生素的 AMR 经济成本。

结果

该模型预测,与当前的临床实践相比,POCCRP 干预措施将导致抗生素处方减少 137 次(6%),不合理处方减少 279 次(12%)。ICER 分别为每例额外正确治疗病例 14.33 美元(医疗服务提供)、11.40 美元(社会)和 9.78 美元(情景分析)。

结论

POCCRP 测试可以改善阿富汗疟疾阴性患者的抗生素处方。成本效益在一定程度上取决于对抗生素处方不合理减少的支付意愿,这只会对近期临床结果产生适度影响,但可能会减少抗生素过度使用带来长期益处。减少抗生素的过度使用是必要的,POCCRP 测试可能会在实现这一目标的其他干预措施中发挥作用。评估政策制定者和捐助者的支付意愿并进行操作试验将有助于确定成本效益,并为决策提供帮助。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/642c/8575266/23e5659a0a48/pone.0258299.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验